Issue 18, 2015

Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line

Abstract

The emergence of multidrug resistance (MDR) is a significant challenge in osteosarcoma chemotherapy. The central element of the MDR phenomenon is P-glycoprotein (P-gp, also called MDR1), an efflux transporter. Schisandrin A (SchA) extracted from Fructus schisandra has been reported to potently reverse MDR. However, the effect of SchA on osteosarcoma and the mechanism through which it inhibits MDR capacity remain unclear. In this study, SchA was tested for its potential to modulate the MDR phenotype and the function of P-gp in MG-63 doxorubicin-resistant (MG-63/DOX) cells. SchA increased the accumulation and retention of intracellular doxorubicin (DOX) in MG-63/DOX cells. Furthermore, it increased the accumulation of rhodamine 123 and decreased its efflux, indicating that SchA blocked P-gp. Furthermore, SchA enhanced DOX-induced apoptosis, reduced the expression of P-gp, and inhibited MDR1 transcription. P-gp overexpression in MG-63 cells resulted in an increase in the IC50 value in response to DOX. Knockdown of P-gp in MG-63/DOX cells resulted in a decrease in IC50 value in response to DOX. Furthermore, P-gp overexpression in MG-63 cells or knockdown in MG-63/DOX cells resulted in changes in both cleaved-PARP and cleaved-Caspase-7 levels in response to DOX. SchA reduced the IC50 of DOX and increased cleaved-PARP and cleaved-Caspase-7 levels in MG-63 cells transfected with the MDR1 expression vector. In addition, SchA inhibited NF-κB signaling, TNF-α-induced p-IκB-α and P-gp levels, and the TNF-α-induced increase in the IC50 values of DOX. Taken together, these results support the potential therapeutic value of SchA as an MDR-reversing agent in chemotherapy for osteosarcoma.

Graphical abstract: Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line

Article information

Article type
Paper
Submitted
11 Nov 2014
Accepted
19 Jan 2015
First published
28 Jan 2015

RSC Adv., 2015,5, 13972-13984

Author version available

Schisandrin A enhances the cytotoxicity of doxorubicin by the inhibition of nuclear factor-kappa B signaling in a doxorubicin-resistant human osteosarcoma cell line

Y. Xia, L. Yang, Z. Wang, C. Guo, C. Zhang, Y. Geng and L. Kong, RSC Adv., 2015, 5, 13972 DOI: 10.1039/C4RA14324H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements